VASH1 in urothelial carcinoma has been previously reported in only two studies.13,25 Zhang et al. investigated VASH1 density in 50 all-stage patients with BCa (17 with MIBC) and reported worse 5-year OS and progression-free survival in patients with high VASH1 density (p < 0.01).13 We previously reported VASH1 expression in 117 patients with upper tract urothelial carcinoma and observed worse 5-year RFS and CSS in patients with high VASH1 density.25 In these reports, most of the patients did not receive NAC. The gene discussed is VASH1; the disease is urothelial carcinoma.